Latest news with #MYSTIC
Associated Press
15-05-2025
- Health
- Associated Press
Altis Labs Unveils New AI-Powered External Control Arm Product Offering at ISPOR 2025
AI-matched digital twins for MYSTIC trial participants emulated the control arm and overall survival treatment effects. 'These findings highlight the potential for imaging-based digital twins to serve as robust external comparators in oncology clinical trials'— Dr. Omar Khan MONTREAL, QUEBEC, CANADA, May 15, 2025 / / -- Altis Labs, Inc. ('Altis') will present findings at ISPOR 2025 demonstrating how real-world digital twins (rwDTs) can replicate control arm outcomes in AstraZeneca's randomized controlled Phase 3 MYSTIC trial in metastatic non-small cell lung cancer (mNSCLC). These results support the launch of Altis' new product offering that enables clinical development teams to generate external controls with AI applied to comprehensive real-world imaging + clinical + outcomes data. Altis applied MYSTIC's eligibility criteria to its multimodal real-world data to identify historical patients treated with relevant standard-of-care (SOC) treatment. AI models processed the real-world baseline CT scans and quantified thousands of spatial imaging biomarkers representing total tumor burden, body composition, and other prognostic features. Using baseline imaging characteristics of each MYSTIC subject, 'matching' rwDTs were identified to generate an External Control Arms (ECAs). AstraZeneca independently evaluated the survival outcomes of the ECAs and compared them to the MYSTIC trial arms, concluding that the ECAs successfully emulated the actual control arm and yielded consistent treatment effect estimates. 'CT Imaging – a 3D reconstruction of the entire patient anatomy – is the most comprehensive data modality already being used in clinical care and oncology trials,' said Felix Baldauf-Lenschen, CEO of Altis. 'It's no surprise that AI applied to this rich data alone can match patients' baseline characteristics to emulate efficacy readouts.' 'These findings highlight the potential for imaging-based digital twins to serve as robust external comparators in oncology clinical trials,' said the presenting author, Dr. Omar Khan, a Clinical Assistant Professor in the Cumming School of Medicine at the University of Calgary and Medical Oncologist at the Arthur J.E. Child Comprehensive Cancer Centre. 'This approach is particularly relevant to help enhance single-arm trials, where comparative evidence is often limited.' Altis' ECA: A New Tool for Smarter Evidence Generation The newly launched ECA product enables sponsors to generate external controls using their clinical trial imaging data and Altis' real-world imaging data + associated survival outcomes. Sponsors can use these ECAs in various ways: • Benchmarking efficacy signal in single-arm trials • Augmenting a control arm to increase statistical power in RCTs • Real-world external comparators to inform reimbursement strategy Altis' models are trained on a proprietary dataset of over 200,000 cancer patients with longitudinal imaging, demographic, diagnostic, treatment, and survival outcomes data, enabling robust matching. The full results are featured at ISPOR 2025, Poster MSR147: Evaluating Imaging Artificial Intelligence (AI) Matching Real-World Digital Twins (rwDTs) Into an External Control Arm (ECA) for MYSTIC: A Phase 3 Clinical Trial in Metastatic Non-Small Cell Lung Cancer (mNSCLC). About Altis Labs Altis Labs is the computational imaging company accelerating clinical trials with AI. Altis has trained proprietary AI models on the industry's largest multimodal training database spanning over 200 million longitudinal images linked to clinical, molecular, and outcomes data. Top 20 biopharmas use Altis' AI models to more confidently analyze data from phase 1-4 clinical trials so that they can bring the most effective novel treatments to patients sooner. For more information, visit follow @AltisLabs on social media, or email [email protected]. Felix Baldauf-Lenschen Altis Labs, Inc. email us here Visit us on social media: LinkedIn X Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Yahoo
06-04-2025
- Business
- Yahoo
Just opened a Stocks and Shares ISA? Here are 10 stocks to consider buying, according to AI
The £20,000 annual allowance of Stocks and Shares ISAs across Britain has just been reset. And with the start of a new tax year, many new investors are entering the market as economic conditions slowly improve and savings rates fall. One of the biggest challenges investors face is building a well-balanced portfolio. But with artificial intelligence (AI) models constantly getting smarter, why not outsource this task to ChatGPT? After tasking the chatbot to build an ISA portfolio, it made 10 recommendations. And some of the suggestions actually look like decent foundational stocks. However, ChatGPT also made some pretty risky and volatile suggestions. In fact, the model doesn't appear to have taken risk tolerance into account at all. The list of stocks that ChatGPT recommended is: AstraZeneca (LSE:AZN) Apple Microsoft Tesla Unilever Diageo Shell Johnson & Johnson NextEra Energy Ørsted The portfolio offers exposure to a variety of industries, such as beverages, pharmaceuticals, consumer staples, energy, technology, and automotive. What's more, half of the companies are listed outside of the UK, with operations spanning the globe, offering even more geographical diversification benefits. The businesses themselves are also well-known industry titans, with large market capitalisations and deep financial pockets that reduce the risk of bankruptcy. And with some touting a long history of paying dividends, this portfolio offers a nice blend of both growth and income investments. Overall, everything appears to be in place. So what's wrong with this ISA portfolio? Despite the large scale of these businesses, several of ChatGPT's suggestions are pretty risky stock picks. For example, Tesla has recently seen almost half of its market-cap wiped out in just the last few months, Diageo has been on a similar decline since 2022, as has Ørsted. Of course, not all of these companies are on a downward trajectory. AstraZeneca is one of these exceptions, and the pharma giant's steady stream of successful clinical trial results has propelled the stock price higher. In fact, it's now the largest enterprise on the entire London Stock Exchange. Sadly, that still doesn't make it a risk-free investment. Clinical trials are notoriously challenging and expensive to execute. And just because it's been enjoying successes recently doesn't mean it will continue to do so. In fact, the company has experienced many painful clinical trial failures over the years. Case in point, in 2017, its phase-three MYSTIC trial failed in the final home stretch, resulting in the AstraZeneca share price collapsing by over 15% in a single day. In other words, investing in pharmaceuticals can be a volatile journey, even among the biggest names, such as AstraZeneca and Johnson & Johnson. Every one of ChatGPT's recommended ISA stocks has its risks, some bigger than others. Diversification can help take some of the sting away. But it's still paramount that investors dig into the details to understand exactly what sort of investments they are making and whether they fit within their risk tolerance limits. The post Just opened a Stocks and Shares ISA? Here are 10 stocks to consider buying, according to AI appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool Zaven Boyrazian has no position in any of the shares mentioned. The Motley Fool UK has recommended Apple, AstraZeneca Plc, Diageo Plc, Microsoft, Tesla, and Unilever. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Sign in to access your portfolio
